Drug General Information (ID: DDIYJI7R5Q)
Drug Name			Miglitol		Drug Info		Insulin degludec		Drug Info
Drug Type		Small molecule				Hormones
Therapeutic Class		Antidiabetic Agents				Insulin/Antidiabetic Agents
Structure

Mechanism of Miglitol-Insulin degludec Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Miglitol				Insulin degludec
Mechanism		Increase the risk of hypoglycemia combined with insulin/insulin secretagogue				Insulin/insulin secretagogue
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Miglitol and Insulin degludec

Recommended Action
Management		Dosage reduction of sulfonylureas and insulin should be considered when prescribed in combination with miglitol. Because miglitol inhibits the hydrolysis of sucrose to glucose and fructose, a source of glucose (dextrose, D-glucose) should be readily available to treat mild to moderate hypoglycemia. Severe hypoglycemia may require the use of either intravenous glucose infusion or glucagon injection

References
1	Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
2	Product Information. Glyset (miglitol). Bayer, West Haven, CT.
3	Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72. [PMID: 6781341]